Merck begins tender offer to buy Terns Pharmaceuticals
This article is a placeholder with "MSN" as its content. Without the actual article text, it is not possible to provide a summary of Merck's tender offer for Terns Pharmaceuticals. The content essentially indicates that the article itself is missing.
Merck launches tender offer to acquire Terns Pharmaceuticals for $53 per share
Merck & Co. has commenced a cash tender offer to acquire all outstanding shares of Terns Pharmaceuticals Inc. for $53.00 per share, following a definitive acquisition agreement from March 25, 2026. Terns' board has recommended shareholders accept the offer, which is set to expire on May 4, 2026. The transaction is subject to shareholder tenders and regulatory approvals, with Merck expecting to close in the second quarter of 2026.
Shareholder Alert: Ademi LLP investigates whether Terns Pharmaceuticals Inc. is obtaining a Fair Price for Public Shareholders
Ademi LLP is investigating Terns Pharmaceuticals (NASDAQ: TERN) regarding potential breaches of fiduciary duty related to its recent transaction with Merck. Terns stockholders are set to receive $53.00 per share in cash, valuing the equity at approximately $6.7 billion. The investigation will examine whether the Terns board of directors is fulfilling its fiduciary duties to all shareholders and if the transaction offers a fair price, especially given the significant penalty clause for competing bids.
43,857 Shares in Terns Pharmaceuticals, Inc. $TERN Acquired by SG Americas Securities LLC
SG Americas Securities LLC has acquired a new position of 43,857 shares, valued at approximately $1.77 million, in Terns Pharmaceuticals (NASDAQ:TERN) during the fourth quarter. This acquisition contributes to the company's high institutional ownership of 98.26%. Despite insider selling activity, analysts have a "Hold" consensus rating with a $56.30 price target, and the company recently surpassed earnings per share estimates.
Capricorn Fund Managers Ltd Takes $6.12 Million Position in Terns Pharmaceuticals, Inc. $TERN
Capricorn Fund Managers Ltd has acquired a new stake of 151,436 shares in Terns Pharmaceuticals, Inc. (NASDAQ:TERN), valued at approximately $6.12 million, making it their 27th largest holding. The article also notes recent insider selling by CEO Amy L. Burroughs and Emil Kuriakose, totaling $3.85 million over the past three months, though corporate insiders still own 1.50% of the stock. Analyst consensus presents a "Hold" rating with an average target price of $56.30, reflecting mixed views despite the stock's recent earnings beat.
Three new Terns employees get 23,316 stock units over 4 years
Terns Pharmaceuticals (Nasdaq: TERN) has granted inducement equity awards totaling 23,316 restricted stock units (RSUs) to three new employees, effective April 1, 2026. These RSUs will vest over four years, contingent on continued service, and were approved by the Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4). The grants serve as a material inducement for the employees to accept employment with the company, which is currently undergoing an acquisition by Merck.
Terns Pharmaceuticals Grants Inducement Shares to New Employees
Terns Pharmaceuticals, a clinical-stage oncology company, has granted equity inducement awards totaling 23,316 restricted stock units (RSUs) to three new employees. These grants, approved by the company's Compensation Committee, vest over four years and are a common strategy in the biotech industry to attract and retain top talent by aligning employee interests with those of shareholders. The awards were made in accordance with Nasdaq Listing Rule 5635(c)(4).
TERN Stock Price, Quote & Chart | TERNS PHARMACEUTICALS INC (NASDAQ:TERN)
TERNS PHARMACEUTICALS INC (NASDAQ:TERN) is a clinical-stage biopharmaceutical company focused on small-molecule drug candidates for liver diseases, oncology, and obesity. The stock currently trades at $52.72, down slightly today but up significantly over the past year. Analysts project a modest price increase, and the company has strong technical ratings but lower fundamental ratings.
Terns Pharmaceuticals (TERN) CMO sells shares to cover RSU taxes
Terns Pharmaceuticals' Chief Medical Officer, Emil Kuriakose, sold 942 shares of common stock at a weighted average price of $52.7526 per share. This sale was non-discretionary and executed solely to cover tax obligations arising from the vesting of a restricted stock unit award. Following the transaction, Kuriakose directly holds 105,673 shares of TERN.
Emil Kuriakose Sells 942 Shares of Terns Pharmaceuticals (NASDAQ:TERN) Stock
Insider Emil Kuriakose sold 942 shares of Terns Pharmaceuticals (NASDAQ:TERN) stock on April 1st for $52.75 per share, reducing his position by 0.88% to 105,673 shares. The company's stock traded down 0.1% on Thursday, with unusually high volume, and has a market capitalization of $6.08 billion. Terns Pharmaceuticals holds an average analyst rating of "Hold" with a price target of $56.30, and institutional investors own 98.26% of the stock.
Press Release: Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
Terns Pharmaceuticals announced inducement grants to three new employees: William P. Seipp, Jing Huang, Ph.D., and Vicki Huang, Ph.D. These grants, comprising stock options and restricted stock units, were approved by the independent compensation committee and are a material inducement essential to their employment, made outside the company's 2019 Equity Incentive Plan. They vest over four years based on continued service.
Terns Pharmaceuticals Reports Inducement Grants To New Employees Under Nasdaq Listing Rule 5635(C)(4)
Terns Pharmaceuticals has announced inducement grants to new employees in accordance with Nasdaq Listing Rule 5635(C)(4). The report, provided by Refinitiv and Thomson Reuters, indicates that these grants are part of the company's hiring practices. Further details or the full report may require logging into a free account.
Terns Pharmaceuticals (NASDAQ:TERN) Issues Earnings Results, Beats Estimates By $0.06 EPS
Terns Pharmaceuticals (NASDAQ:TERN) reported its quarterly earnings, beating consensus estimates by $0.06 with an EPS of ($0.24). Despite its unprofitability, the stock is near its 1-year high, reflecting strong market interest. The company has seen significant insider selling, including shares from its CEO, while institutional ownership remains high at 98.26%.
Merck to buy Terns Pharmaceuticals (NASDAQ: TERN) for $53 per share in cash
Terns Pharmaceuticals is being acquired by Merck Sharp & Dohme LLC for $53 per share in cash, a deal that would make Terns a wholly-owned Merck subsidiary and delist its stock. The acquisition highlights Terns' lead oncology asset, TERN-701 for chronic myeloid leukemia, which has shown promising Phase 1/2 trial data. Terns ended 2025 with strong liquidity of $1.02 billion in cash and marketable securities but continues to report net losses, financing operations primarily through equity offerings.
Terns Pharmaceuticals 10-K: $0 Revenue, $(1.03) EPS
Terns Pharmaceuticals reported no product revenue and a net loss of $96.207 million, or $(1.03) per share, for the year ended December 31, 2025, due to its focus on clinical development over commercial sales. The company announced a pending merger agreement with Merck at $53 per share, creating strategic uncertainty, while also advancing its oncology programs and completing an equity raise to fund development. Terns is prioritizing oncology, discontinuing TERN-601, and seeking partners for metabolic candidates to reallocate resources.
Terns Pharmaceuticals faces final earnings under acquisition cloud
Terns Pharmaceuticals is preparing to report its fourth-quarter earnings, potentially for the last time as an independent company, following a $6.7 billion acquisition agreement with Merck. The deal has sparked debate among analysts and investors who question if the offer fully values Terns, especially its experimental chronic myeloid leukemia treatment, TERN-701, leading to speculation about potential competing bids. The upcoming earnings report will focus less on quarterly metrics and more on any developments regarding the acquisition, including the possibility of a superior offer emerging.
Merck nears deal to buy Terns Pharmaceuticals
This article mentions that Merck is reportedly close to finalizing a deal to acquire Terns Pharmaceuticals. No further details about the acquisition, such as the financial terms or strategic rationale, are provided in this brief excerpt.
Merck’s deal for Terns sparks debate over a possible biotech bidding war
Merck's $6.7 billion acquisition of Terns Pharmaceuticals is sparking debate among analysts and investors due to its lower-than-anticipated price for Terns' promising chronic myeloid leukemia drug, TERN-701. While some see it as a fair deal given Terns' past struggles, others argue the offer undervalues the drug's blockbuster potential, suggesting a bidding war could emerge. The deal is crucial for Merck as it looks to offset future revenue declines from its top-selling drug Keytruda.
Merck to buy Terns in $6.7B bet on a ‘differentiated’ leukemia drug
Merck & Co. is set to acquire Terns Pharmaceuticals for $6.7 billion to bolster its cancer drug portfolio, specifically targeting chronic myeloid leukemia with Terns' early-stage drug, TERN-701. This acquisition is part of Merck's strategy to diversify its pipeline ahead of Keytruda's patent expiration, and despite a modest premium, analysts suggest the "differentiated" nature of the asset could attract competing bids. TERN-701 has shown promising early results, potentially challenging existing market leaders like Novartis’ Scemblix.
Shareholder Alert: The Ademi Firm investigates whether Terns Pharmaceuticals Inc. is obtaining a Fair Price for Public Shareholders
Ademi LLP is investigating Terns Pharmaceuticals (NASDAQ: TERN) regarding its recently announced transaction with Merck. The firm is examining whether Terns is securing a fair price of $53.00 per share for public shareholders, given the substantial benefits insiders will receive and a significant penalty clause for competing bids. Ademi LLP is inviting shareholders to join their investigation into potential breaches of fiduciary duty by Terns' board of directors.
Merck nears $6 billion all-cash deal to buy Terns Pharma, FT reports
Merck is reportedly nearing a $6 billion all-cash acquisition of Terns Pharma to enhance its oncology portfolio, particularly as its blockbuster drug Keytruda approaches patent expiration. The deal, which aims to boost Merck's cancer division, is said to be in advanced negotiation stages and could be finalized within days. Following the news, shares of Terns Pharma, which specializes in chronic myeloid leukemia treatments, surged by about 10% in after-hours trading.
Merck nears $6 billion acquisition of Terns Pharma to boost cancer portfolio, FT reports
Merck is reportedly close to acquiring biotech firm Terns Pharma for approximately $6 billion in an all-cash deal. This move aims to bolster Merck's cancer portfolio and support its new dedicated oncology division, especially as its blockbuster drug Keytruda faces patent expiration in 2028. Following the news, Terns Pharma's shares saw a significant rise in after-hours trading.
Acorn Capital Sells $5.2M in Terns Pharma Shares, Remains Top Holding | 2026 Update - News and Statistics
Acorn Capital Advisors reduced its stake in Terns Pharmaceuticals by selling 225,000 shares for approximately $5.20 million in Q4 2025. Despite this divestment, Terns Pharmaceuticals remains Acorn Capital's largest single investment, comprising 24% of its total portfolio. Terns Pharmaceuticals is a clinical-stage biotech company focusing on treatments for non-alcoholic steatohepatitis and obesity, with a current market valuation of around $5.5 billion.
Terns Pharmaceuticals (NASDAQ:TERN) Lowered to "Sell" Rating by Wall Street Zen
Wall Street Zen downgraded Terns Pharmaceuticals (NASDAQ:TERN) from a "hold" to a "sell" rating on Saturday, March 21, 2026, despite a consensus "Buy" rating from other analysts with an average price target of $58.11. This comes amidst accelerated insider selling, with CEO Amy L. Burroughs among those who sold shares, leading to insiders holding only 1.50% ownership. The stock opened at $48.44 and is trading near its 52-week high of $50.00, with a market capitalization of $5.03 billion.
Terns Pharmaceuticals (NASDAQ:TERN) Sets New 12-Month High - Should You Buy?
Terns Pharmaceuticals (NASDAQ:TERN) reached a new 52-week high of $49.53 on heavy volume. Analysts have largely given the stock a "Buy" rating with an average target price of $58.11, following several target increases. However, insider selling, including by the CEO, which reduced insider ownership to 1.5%, could be a warning sign for potential investors.
Superstring Capital Reduces Terns Pharmaceuticals Holding in Late 2025 - News and Statistics
Superstring Capital Management reduced its stake in Terns Pharmaceuticals during Q4 2025 by selling 345,869 shares valued at $7.99 million. Despite this reduction, Terns Pharmaceuticals remains a significant holding, comprising 9.6% of Superstring Capital's assets under management and ranking as its second-largest investment. Terns Pharmaceuticals, a clinical-stage biopharmaceutical company with a market valuation of $4.9 billion, saw its shares rise significantly over the past year and maintains a strong cash position following a substantial capital raise.
Amy Burroughs Sells 14,583 Shares of Terns Pharmaceuticals (NASDAQ:TERN) Stock
Amy Burroughs, CEO of Terns Pharmaceuticals (NASDAQ:TERN), sold 14,583 shares of the company's stock for approximately $681,172, reducing her stake by 4.8%. Following the sale, she directly owns 288,976 shares valued at about $13.5 million. The stock currently trades around $46.47, near its 52-week high, with a market capitalization of $4.82 billion and an average analyst rating of "Buy."
Terns Pharmaceuticals (NASDAQ: TERN) CEO sells exercised shares under plan
Terns Pharmaceuticals (NASDAQ: TERN) CEO Amy L. Burroughs reported an exercise-and-sell transaction. On March 16, 2026, she exercised options for 14,583 shares at $4.64 per share and subsequently sold all of these shares in open-market transactions at weighted average prices of $46.5657 and $47.3024. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted in June 2025, leaving her with a direct holding of 288,976 shares and an indirect holding of 8,319 shares.
Terns Pharmaceuticals CEO Amy L. Burroughs Sells Shares
Amy L. Burroughs, CEO of Terns Pharmaceuticals, sold 14,583 shares of common stock for a total of $681,108 on March 16, 2026. The sales were executed under a Rule 10b5-1 trading plan at weighted average prices of $46.5657 and $47.3024 per share. Following these transactions, Burroughs directly owns 288,976 shares and indirectly holds 8,319 shares.
Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Receives Consensus Recommendation of "Buy" from Analysts
Terns Pharmaceuticals (NASDAQ:TERN) has received a consensus "Buy" rating from analysts, with an average 12-month target price of $58.11. Despite this positive outlook, there has been notable insider selling, with CEO Amy L. Burroughs selling 71,339 shares, significantly reducing her stake, and other insiders selling over $5.88 million worth of shares recently. Institutional ownership remains very high at 98.26%, and the stock is currently trading near its 52-week high with a market cap of $4.83 billion.
Vestal Point Capital's Major Investment in Terns Pharma | 2026 - News and Statistics
Vestal Point Capital has made a significant investment in Terns Pharmaceuticals, acquiring 4.5 million shares valued at $181.8 million, making it the firm's third-largest holding. Terns Pharmaceuticals is a clinical-stage biotechnology company focusing on small-molecule treatments for conditions like non-alcoholic steatohepatitis and obesity. The company, which has seen its stock price substantially increase over the past year, maintains a strong cash position to fund its operations and pipeline development.
Zacks Industry Outlook Features Terns Pharmaceuticals, ADMA Biologics, ANI Pharmaceuticals, and Liquidia
Zacks Equity Research has analyzed Terns Pharmaceuticals (TERN), ADMA Biologics (ADMA), ANI Pharmaceuticals (ANIP), and Liquidia Corp. (LQDA) within the biotechnology sector. Despite economic challenges, the biotech industry shows strong performance driven by robust earnings, regulatory approvals, and M&A activities, especially with the integration of AI in drug development. Key stocks highlighted with strong potential include Liquidia, ANI Pharmaceuticals, ADMA Biologics, and Terns Pharmaceuticals, all with positive Zacks Ranks and promising advancements in their respective therapeutic areas.
Terns Pharmaceuticals (TERN) Is Up 8.6% After Pipeline Update And Index Inclusion News
Terns Pharmaceuticals (TERN) saw an 8.6% increase in its stock after announcing updated pipeline timelines and its inclusion in a STOXX benchmark index. While this offers clearer development visibility and institutional interest, significant concerns remain regarding the company's lack of revenue, persistent losses, and valuation. The company's future hinges on its oncology pipeline, specifically TERN-701, and efficient management of its substantial cash reserves amidst ongoing dilution risks.
Terns Pharmaceuticals’ Valuation Reassessed Amid Latest Developments
Terns Pharmaceuticals Inc. (NASDAQ: TERN) saw its stock rise by 6.8% following promising clinical trial results, prompting a reassessment of its valuation. Despite this positive movement, the company faces financial challenges, including revenue constriction and significant operating costs, underscoring the need for strategic recalibration and cost-effective innovation in a competitive biopharma landscape. Investors are advised to monitor future quarterly disclosures for insights into the company's recovery and competitive positioning.
Terns Pharmaceuticals shares rise as investors focus on recent presentation, index-addition notice, and upcoming earnings
Terns Pharmaceuticals (TERN) shares rose 5.4% today due to renewed attention on the company's near-term milestones from a corporate presentation, incremental demand from a benchmark index addition, and positioning ahead of its next earnings report. The pharmaceutical company has a refreshed March 2026 presentation highlighting its pipeline and milestones, is being added to a STOXX benchmark index effective March 23, 2026, and has received supportive "Strong Buy" ratings from analysts. Insider trading over the last six months shows 10 sales and 0 purchases, while institutional investors have mixed activity, with some large removals and additions in Q4 2025.
Terns Pharmaceuticals CEO outlines strategy to advance novel leukemia therapy
Terns Pharmaceuticals CEO Amy Burroughs discussed the company's evolving oncology strategy and its focused approach to developing a novel therapy for chronic myeloid leukemia on The Bio Report podcast. This conversation highlighted Terns Pharmaceuticals' commitment to advancing targeted therapies to meet unmet medical needs in oncology, particularly for challenging blood cancers. The company is actively shaping its research pipeline to accelerate progress in this area.
TERN: TERN-701 shows best-in-disease efficacy and safety in CML, with pivotal trials and launch funded
Terns Pharmaceuticals' TERN-701 has demonstrated superior efficacy and a clean safety profile in treating Chronic Myeloid Leukemia (CML), even in refractory and mutation-positive patients. The company is advancing plans for dose selection and pivotal studies, having already secured funding for the drug's commercialization. This development suggests a significant advancement in CML treatment options.
Dynamic Technology Lab Private Ltd Grows Stock Position in Terns Pharmaceuticals, Inc. $TERN
Dynamic Technology Lab Private Ltd significantly increased its stake in Terns Pharmaceuticals, Inc. (NASDAQ:TERN) by 237.2% in the third quarter, now owning 66,576 shares valued at $500,000. Other institutional investors also adjusted their positions in Terns Pharmaceuticals, which has generally received "Buy" ratings from analysts with a consensus price target of $58.11. Insider activity shows sales by CEO Amy L. Burroughs and Emil Kuriakose, though company insiders still hold a notable percentage of the stock.
TERN: TERN-701 shows superior efficacy and safety in CML, positioning for major market impact
Terns Pharmaceuticals (TERN) is focusing on its drug TERN-701 for Chronic Myeloid Leukemia (CML), which has demonstrated superior efficacy and safety in third-line-plus patients compared to current competitors. The company sees a significant market opportunity and is progressing with pivotal studies while planning for frontline trials. This information is based on an AI-generated summary of Terns Pharmaceuticals' Leerink Global Healthcare Conference 2026 Audio Transcript.
DLD Asset Management LP Cuts Stake in Terns Pharmaceuticals, Inc. $TERN
DLD Asset Management LP significantly reduced its stake in Terns Pharmaceuticals (NASDAQ:TERN) by 73% in the third quarter, selling 27,047 shares and retaining 10,000 shares. Despite this, other institutions like Vanguard and JPMorgan increased their positions, contributing to an overall institutional ownership of approximately 98.26%. Company insiders also sold shares, even as Wall Street analysts maintain a "Buy" rating with a consensus price target of $58.11.
15 Stocks with the Biggest Hedge Fund Momentum
This article identifies Terns Pharmaceuticals Inc. (NASDAQ: TERN) as one of 15 stocks experiencing significant hedge fund momentum, with a notable increase in hedge fund holders in Q4 2025. Leerink Partners initiated coverage on Terns Pharmaceuticals with an Outperform rating and a $58 price target, citing the potential of its drug candidate TERN-701 for chronic myeloid leukemia and its promising early Phase 1 trial data. The firm projects substantial market opportunities for TERN-701, building on the success of similar allosteric inhibitors in the market.
Does Rising Hedge Fund Interest in Terns (TERN) Reveal a Deeper Bet on Single-Asset Biotech Risk?
Hedge fund interest in Terns Pharmaceuticals (TERN) is increasing, driven by the potential of its lead asset, TERN-701, for chronic myeloid leukemia. While Leerink Partners initiated bullish coverage seeing a multi-billion dollar opportunity, the company faces significant risks including zero revenue, ongoing losses, and potential dilution. Investors are cautioned to weigh the high risk of a single-asset biotech against the speculative upside.
TERN Financials: Income Statement, Balance Sheet & Cash Flow
This article provides a detailed financial overview of Terns Pharmaceuticals, Inc. (TERN), covering its income statement, balance sheet, and cash flow for both annual and quarterly periods, derived from SEC filings. Analysis of key metrics reveals the company's financial health, including a weak Piotroski F-Score and low earnings quality, with TERN reporting negative net income, EBITDA, and free cash flow in fiscal year 2024. The article also includes frequently asked questions about TERN's profitability, EPS, cash flow, assets, and various financial ratios.
Analyst Optimistic on Terns (TERN) Citing Possible $4.8B Market for Upcoming Leukemia Drug
Leerink Partners initiated coverage on Terns Pharmaceuticals Inc. (NASDAQ:TERN) with an Outperform rating and a $58 price target, citing significant market potential for its upcoming chronic myeloid leukemia drug, TERN-701. The firm projects a $4.8 billion opportunity for TERN-701, with an additional $1.4 billion in second-line revenues, due to its potential best-in-class profile and clean safety data from early trials. Terns Pharmaceuticals has also seen increased hedge fund interest, adding 42 new holders in Q4 2025.
Analyst Optimistic on Terns (TERN) Citing Possible $4.8B Market for Upcoming Leukemia Drug
Leerink Partners has initiated coverage on Terns Pharmaceuticals Inc. (TERN) with an Outperform rating and a $58 price target. The firm is optimistic about TERN-701, the company's upcoming chronic myeloid leukemia drug, projecting a market opportunity of $4.8 billion, with an additional $1.4 billion in second-line and beyond peak revenues. Early Phase 1 data for TERN-701 from the CARDINAL trial suggest a best-in-class profile, showing higher molecular response rates and a clean safety profile.
Terns Pharmaceuticals (TERN) Valuation Check After Strong Recent Share Price Run And CML Narrative Shift
Terns Pharmaceuticals (TERN) has seen a significant share price increase, with a 16.61% 1-month return and a 45.57% 3-month return, driven by its clinical stage focus on oncology and obesity. A valuation narrative suggests the company is 58.5% undervalued at a fair value of $98.57, based on the potential of TERN-701 in the CML market, projecting $4.5 billion in peak annual sales with an 80% probability of success. However, traditional metrics show a high P/B ratio compared to peers, and the company still reports $0 revenue and a $94.435 million loss, indicating that future success is heavily baked into the current price.
Analyst Optimistic on Terns (TERN) Citing Possible $4.8B Market for Upcoming Leukemia Drug
Leerink Partners initiated coverage on Terns Pharmaceuticals Inc. (NASDAQ:TERN) with an Outperform rating and a $58 price target, driven by the potential of TERN-701 for chronic myeloid leukemia. The firm projects a $4.8 billion market opportunity for TERN-701, with an additional $1.4 billion in second-line revenues. Early Phase 1 data suggests TERN-701 could have a best-in-class profile, building on the success of similar allosteric inhibitors.
Terns Pharmaceuticals to Participate in Upcoming March Investor Conferences
Terns Pharmaceuticals, a clinical-stage oncology company, announced its participation in several investor conferences in March. Senior management will attend TD Cowen's 46th Annual Health Care Conference, Leerink Global Healthcare Conference, Barclays 28th Annual Global Healthcare Conference, and The Citizens Life Sciences Conference. Live webcasts of the fireside chats will be accessible on the company's investor relations page.
Terns Pharmaceuticals to Participate in Upcoming March Investor Conferences
Terns Pharmaceuticals announced its participation in multiple investor conferences in March 2026, including the TD Cowen's 46th Annual Health Care Conference, Leerink Global Healthcare Conference, Barclays 28th Annual Global Healthcare Conference, and The Citizens Life Sciences Conference. Senior management will engage in fireside chats and 1x1 meetings to discuss the company's clinical-stage oncology programs. Live webcasts of the fireside chats will be available on their investor relations website.
Terns Pharmaceuticals to Participate in Upcoming March Investor Conferences
Terns Pharmaceuticals, a clinical-stage oncology company, announced its participation in four investor conferences in March 2026. Senior management will present at the TD Cowen's 46th Annual Health Care Conference, Leerink Global Healthcare Conference, Barclays 28th Annual Global Healthcare Conference, and The Citizens Life Sciences Conference. The company will discuss its lead program, TERN-701, an allosteric BCR-ABL inhibitor for CML.
